Differential splicing from the bcl-X gene generates several isoforms with opposite effects on the apoptotic response. To explore the mechanism controlling the balance between the various isoforms, we have characterized the 5 region of the mouse bcl-X gene. We identified three new promoters in addition to the two previously described (Grillot, D. A., M., G.-G., Ekhterae, D., Duan, L., Inohara, N., Ohta, S., Seldin, M. F., and Nú ñ ez, G. (1997) J. Immunol. 158, 4750 -4757). These five promoters (P1-P5) would give rise to at least five mRNAs with different 5-untranslated region, all sharing the same translation initiation site. Except for the product of the most proximal promoter (P1), the other mRNAs are generated by alternative splicing of noncoding exons to a common acceptor site located in the first translated exon. Reverse transcriptase-polymerase chain reaction, primer extension, and RNase protection assays demonstrate a tissue-specific pattern of promoter usage. P1 and P2 are active in all tissues analyzed, whereas the other three promoter show tissue-specific activities. P3 is active in spleen, liver, and kidney, P4 is active in uterus and spleen, and P5 is active in spleen, liver, brain, and thymus. We present evidence suggesting that promoter selection influences the outcome of the splice process. Transcripts from P1 generate mainly the mRNA for the long isoform Bcl-X L , whereas transcripts from P2 generate mRNAs for the isoforms Bcl-X L , Bcl-X S , and Bcl-X ␥ and transcripts from P3 yield mainly mRNAs for the isoform Bcl-X ␥ . Our results suggest a key role of promoter choice in determining alternative splicing and, thus, the balance of Bcl-X isoforms.
The term apoptosis refers to a physiologic and genetically controlled program for cells to commit suicide. Control of cell survival is of central importance for the formation of various organs during embryogenesis as well as in adult tissues with high cell turnover such as reproductive glands and the lymphoid system. Moreover, disabling programmed cell death may be a critical step in tumorogenesis. Cells undergo apoptosis not only in response to external signals but also by a cell autonomous genetic program controlled at several checkpoints. One crucial control relies on the ability of the cell to sense changes in the ratio between members of the Bcl-2 family. The bcl-2 oncogene was first identified in human B-cell lymphomas in the context of a chromosomal translocation, which placed it within the immunoglobulin locus (2) . bcl-2 promotes cell survival by inhibiting apoptosis induced under a wide variety of circumstances, suggesting that it is a ubiquitous inhibitor of cell death triggered by multiple pathways (3) . bcl-2 is the founding member of a growing multigene family with many representatives in mammals, including bcl-X, bax, bak, and mcl-1, which can either promote or prevent apoptosis (4 -7). Bcl-2-related proteins have a putative transmembrane domain at their carboxyl terminus and are found associated with mitochondrial, endoplasmic reticulum, and nuclear membranes (8) . The various members of the Bcl-2 family can form homo-and heterodimers, which exert opposite effects on apoptosis. For instance, whereby Bax homodimers are formed upon death stimuli and promote apoptosis, Bax/Bcl-2 heterodimers or Bcl-2 homodimers prevent apoptosis (9) .
It has been suggested that members of the bcl-2 gene family control mitochondrial membrane permeability during apoptosis by regulating the electrical and osmotic homeostasis of mitochondria (10, 11) . Those that prevent apoptosis inhibit release of cytochrome c, whereas those that promote programmed cell death induce this release. According to the mechanism of action suggested by Shimizu et al. (10) , proapoptotic bcl-2 family members accelerate the opening of the mitochondrial porin channel (also named voltage-dependent anion channel), whereas the anti-apoptotic members close this channel by binding directly to it (10) .
Bcl-X is highly related to Bcl-2 and exists in several isoforms generated by alternative splicing (4) (Fig. 1) . Some of these isoforms seem to have a ubiquitous expression, whereas others are expressed in a tissue-specific manner or in response to specific stimuli. The large isoform, Bcl-X L , protects cells against apoptosis, whereas a short isoform, Bcl-X S , antagonizes cell death inhibition by interacting with Bcl-X L and Bcl-2 (4). The cDNA of a third Bcl-X isoform, Bcl-X ⌬TM , was cloned in mouse and shown to be generated by alternative splicing of the carboxyl-terminal transmembrane domain of bcl-X (12) . As a consequence, the protein localizes diffusely throughout the cytosol. Bcl-X ⌬TM was found to prevent programmed cell death (12) . A fourth isoform Bcl-X ␤ , promotes apoptosis and seems to be specifically expressed in cerebellum, heart, and thymus (13) . Finally, a fifth isoform named Bcl-X ␥ was recently identified as an antiapoptotic protein, which is induced in lymphocytes and correlates with T-receptor expression (14) .
Although Bcl-2 and Bcl-X L are both apoptotic inhibitors, their functions are not redundant since they are not found in the same cell types nor at the same developmental stages (15) . Moreover, contrary to the bcl-2 knockout mice, mice lacking bcl-X die around embryonic day 13 due to extensive postmitotic neuronal death (16) .
The genomic structure of the human and mouse bcl-X genes have been recently described (1). The gene has been shown to contain two distinct TATA-less promoter regions. One is located at position Ϫ149 to Ϫ142 relative to the translation initiation site and contains a consensus YYAN(T/A)YY initiator element (Inr), whereas the other is located farther upstream (nucleotides (nt) 1 655) within a GC-rich region and contains several consensus Sp1 binding motifs (1) . However, several lines of evidence support the existence of longer bcl-X transcripts extending farther upstream and suggest the presence of at least one additional promoter (8, 14) .
Here we present a detailed analysis of the 5Ј-flanking region of the mouse bcl-X gene, including several kilobases upstream from the previously described promoters P1 and P2 (1) . Three TATA consensus regions were found located at positions Ϫ1886, Ϫ2721, and Ϫ3412 upstream of the translation initiation site. We named these regions as promoter P3, P4, and P5, respectively. Each of these promoters shows tissue-selective expression, suggesting that tissue-specific factors may be involved in controlling bcl-X transcription. The significance of the utilization of different promoters is not clear, but promoter choice could play a key role in the control of bcl-X expression in response to different stimuli by influencing the splicing process and, thus, leading to the synthesis of specific Bcl-X isoforms (17) . RT-PCR with specific oligonucleotides for the cDNAs belonging to each 5Ј-untranslated region (5Ј-UTR) reveals that activation of promoter P1 generates mainly Bcl-X L , whereas bcl-X ␥ is generated from transcripts containing exon B or exon C and originating from promoters upstream of P1. Our results support the notion that the generation of specific spliced products depends on the 5Ј-leading exon present on the mRNA and that alternative promoter usage could be a key mechanism controlling the expression of different Bcl-X isoforms.
MATERIALS AND METHODS
Plasmid Constructions and DNA Sequencing-pNM1-9 SalI vector contains a 10-kilobase DNA fragment from the 5Ј region of the mouse bcl-X gene cut from the plasmid pNM1-9 (kindly provided by N. Motoyama) with SalI enzyme and subcloned into SalI site of pBluescriptKS plasmid. pNM1-9Eag I is a subclone containing a 9.6-kilobase fragment from pNM1-9 cut with EagI and religated. DNA sequencing was performed by SeqLab (Göttingen, Germany).
Isolation of Total RNA and RNA Analysis-CF1 male and female mice were sacrificed by cervical dislocation, and total RNA was prepared from fresh tissues by the guanidinium thiocyanate-phenolchloroform extraction method (18) . RNase protection assays were performed as described below (19) . For preparing the P1 riboprobe, plasmid pNM1-9SalI was digested with MaeIII and transcribed by T3 RNA polymerase. The full-length transcribed riboprobe was 558 bp. For preparing the P2 riboprobe, plasmid pNM1-9EagI was digested with EcoRI and transcribed by T7 RNA polymerase; the full-length transcribed riboprobe was 495 bp. [␣-
32 P]CTP (Amersham Pharmacia Biotech)-radiolabeled RNA probes were prepared using a kit according to the instructions of the manufacturer (Promega, Madison, WI) and as described before (20) . The probes were coprecipitated with RNA samples, dissolved in hybridization buffer, denatured at 95°C for 10 min, and hybridized at 52°C for 18 h. After digestion with RNase A and T 1 followed by digestion with proteinase K, the samples were precipitated, denatured, and subjected to electrophoresis on a 6% denaturing acrylamide gel.
For primer extension analysis primers, E-rev (5Ј-TAGATCGGAAT-GGACCCTGGCT-3Ј, D-rev (5Ј-AAATGAGCTATAACTCAGTTTT-TCAA-3Ј), and C-rev (5Ј-AGAAAGGGACTGGCATCGAGAC-3Ј), corresponding to the reverse complement of nt Ϫ3223 to Ϫ3244 (primer E-rev), nt Ϫ2548 to Ϫ2573 (primer D-rev), and nt Ϫ1754 to Ϫ1775 (primer C-rev), were used. RNA (30 g) was precipitated and resuspended in 12 l of annealing buffer (120 mM KCl, 24 mM Tris-HCl, pH 8, 5 ϫ 10 5 cpm of 32 P-labeled primer), denaturated at 75°C for 10 min, and hybridized at 39°C for 25 min. After hybridization, the reaction was extended with 50 units of Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) in 30 l of reaction mixture (60 mM Tris-HCl, pH 8, 20 mM KCl, 10 mM MgCl 2 , 1.5 mM dithiothreitol, 0.6 mM each dNTP) at 39°C for 1 h. The reaction was stopped by the addition of 80 l of stop mixture (150 mM NaCl, 15 mM EDTA, 0.75% SDS) followed by phenol-chloroform extraction and ethanol precipitation. The radiolabeled DNA was electrophoresed through a 6% polyacrylamide/urea gel in parallel with sequencing reactions from the genomic bcl-X cloned into pBluescript or with radiolabeled pBR322 MspI size marker.
RT-PCR and Sequence of the 5Ј-Untranslated Region of bcl-X cDNAs-For reverse transcription 4 g of total RNA was used. The first cDNA strand was synthesized with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) and oligo(dT) 17 , as reverse complementary primer. For PCR amplification the oligonucleotide primer ATG-rev (5Ј-AGGAGAGAAAGTCGACCACCAGCTCCCGG-TTGCTCTGAGA-3Ј), corresponding to nt ϩ40 to ϩ3 from the ATG, was used as the reverse complementary primer. Primers P3L (5Ј-GGACT-AGTCCTAGATTGAAGGAATGTGAACCATAAACGTTCCACGCG-3Ј), P4L (5Ј-CCAGGATCTGAGTTCCACTCTTGAACAGAATTAACGC-3Ј, and P5L (5Ј-GGACTAGTCCGTGGAGGACACACACACCATTCGGAT-CCCATTAGA-3Ј) (nt Ϫ1858 to Ϫ1821, nt Ϫ2692 to Ϫ2656, and nt Ϫ3310 to Ϫ3276, respectively) were used as forward primers. The cDNA pool (2 l AA-3Ј), and P5s (5Ј-CATTCGGATCCCATTAGAGTTGCTT-3Ј) (nt Ϫ1779 to Ϫ1754; nt Ϫ2600 to Ϫ2577; and nt Ϫ3293 to Ϫ3269, respectively). Primer AI-rev (5Ј-CCAGGATCCAAAGCCAAGATAAGGTT-3Ј) was used as the reverse primer. PCR was performed by 30 cycles (96°C for 35 s, 60°C for 20 s, and 72°C for 1 min) and a final extension at 72°C for 10 min.
PCR products were purified by electrophoresis in 1.6% agarose gel, and the different bands were extracted from agarose and purified with clean up kit (DNA Clean-up system, Promega). Sequence analysis was performed by SeqLab (Göttingen, Germany).
RT-PCR and Southern Blots of the Specific bcl-X-spliced ProductscDNAs were prepared as described above. For PCR amplification, the oligonucleotides were used as forward primers: P1 (5Ј-CCTGAAGCTC-TCTCTCTCTCTTCA-3Ј) P2L (5Ј-GACTAGTCCAGGTTGTGAGGGGG-CAGGTTCCTAAGCTTCGCAATTCCTCT-3Ј) (nt Ϫ137 to Ϫ114 and nt Ϫ619 to Ϫ577, relative to the ATG translation start codon, respectively) and P3L. The oligonucleotides S/L-rev (5Ј-GTAGAGTGGATGGTCAG-TG-3Ј) and ␥-rev (5Ј-TTGAACTTCCGATCCTTCTGTTTCC-3Ј) (corresponding to the 5Ј-end of each specific second translated exon) were used as reverse primers in order to amplify bcl-X L/S and bcl-X ␥ isoforms, respectively. For amplification of the bcl-X ␥ isoform it was necessary to perform a semi-nested PCR using, in the second round, the oligonucleotide AII-rev (5Ј-ACCACCAGCTCCCGGTTGCTCTGAGAC-AT-3Ј) (corresponding from nt ϩ1 to ϩ26 from the translation initiation site) as reverse primer. For amplification of bcl-X S/L isoforms (corresponding to the samples belonging to spleen, brain, and liver), it was also necessary to perform a semi-nested PCR using, in the second round, the oligonucleotide S/L(II)-rev (5Ј-CCCGTAGAGATCCACAAA-AGTGTC-3Ј) as the reverse primer. PCR products were resolved by electrophoresis in 1.6% agarose gel and transferred to a nylon plus membrane (Qiabrane) with NaOH (0.4 M) as the transfer solution. Southern blots were performed using a fragment containing exon A of mouse bcl-X as the hybridization probe. The membranes were incubated in the prehybridization buffer (potassium phosphate (120 mM), pH 7.2, 10% polyethylene glycol (M r 8000), 7% SDS, NaCl (250 mM), 50% formamide, and 100 g/ml calf thymus DNA) at 42°C for 2 h. Then membranes were hybridized in the same solution with the 32 P-labeled probe at 42°C overnight. A wash was carried out 2ϫ 5 min at room temperature in 2ϫ SSC (1ϫ SSC ϭ 0.15 M NaCl and 0.015 M sodium citrate), 0.5% SDS followed by 2ϫ 5 min at 50°C in 2ϫ SSC, 0.1% SDS. Membranes were exposed between 2 and 5 days.
RESULTS

Evidence for Transcription Initiation Upstream of the P2
Promoter-An RNase protection assay with a probe encompassing the P1 promoter ( Fig. 2A) yielded two protected fragments: a doublet of 176 nt and another of 147 nt. The 176-nt fragments originate from transcripts initiated at the P1 promoter, which were detected in all tissues tested, including uterus, spleen, heart, liver ( Fig. 2A, lanes 2-5) as well as in lung, thymus, brain, and kidney (data not shown). The 147-nt fragments could correspond to transcripts initiated upstream of P1 and spliced to a consensus 3Ј-acceptor splice site located at position Ϫ112 from the ATG. In principle these transcripts could also originate from initiation around this region, but there is no obvious consensus site, and previous studies using primer extension assays did not detect transcripts initiating around Ϫ112 (1). A comparison of the intensity of the 147-nt and the 176-bp bands suggests that most of the transcripts hybridizing with this probe are initiated upstream of the P1 promoter. The origin of the minor 125-nt fragments is unclear, but they could correspond to another previously described start site at position Ϫ96 (1) or to exon B.
RNase protection assays with a probe encompassing the P2 promoter revealed three main bands (Fig. 2B) . Two of them, the 104-nt and 124-nt bands, represent protected products starting at the P2 promoter located 656 nt upstream of the translation start site (Fig. 2B, top) . The 124-nt fragment extends to the end of the probe. The 104-nt fragment corresponds to a transcript extending to a 5Ј-donor splice site located at nt Ϫ553 from the ATG start codon. The identity of this fragment was confirmed by sequencing the cDNA, which we named bcl-X B1 and which encompasses the sequences of exon B spliced to the 3Ј-splice acceptor site of exon A (see the scheme in Fig. 5 and the nucleotide sequence in Fig. 6A ). Transcripts from P2 were detected in spleen and heart (Fig. 2B: lanes 3 and 4) and in very low amounts in uterus and liver (lanes 2 and 5) . The P2 promoter was also active in other tissues, such as thymus and kidney (data not shown). The protected 400-nt band could correspond to transcripts of exon B initiated upstream of P2 and extending to the 5 Ј-splice donor site at Ϫ553. This signal was stronger than the transcripts initiated at P2 in uterus, heart, and liver but weaker in spleen, suggesting differential promoter usage in different tissues. The existence of these kind of transcripts was supported by RT-PCR cloning and sequencing of a fragment extending from Ϫ1310 to Ϫ460 (data not shown). The larger fragments at the top of the gel correspond to the residual intact probe. Other minor bands were not reproducibly observed.
Three Novel Promoter Regions-To explore the presence of additional promoter regions upstream of P2, we sequenced 3.42 kilobases upstream of the ATG start codon in mouse bcl-X gene (Fig. 3) . Recently, a nucleotide sequence of the 5Ј-region (6447 nt) of the mouse bcl-X gene was deposited at the GenBank TM (accession number AF088904) that is virtually identical to the one that we determined. Inspection of the nucleotide sequence revealed a putative 3Ј-acceptor splice site at position Ϫ1468 from the ATG start codon, suggesting a maximal length for exon B of 1271 bp (from nt Ϫ1468 to Ϫ197; see the nucleotide sequence in Fig. 3 and the scheme in Fig. 5 ). In addition, several putative TATA boxes were observed between the nt Ϫ3420 and Ϫ1870, of which only three, located at Ϫ1886 (P3), Ϫ2721 (P4), and Ϫ3412 (P5), showed activity in transcript analysis. Primer extension assays were performed to map the initiation sites of transcripts corresponding to these three TATA boxes. Three reverse complementary oligonucleotides with sequences located downstream P3 (primer C-rev), P4 (primer D-rev), and P5 (primer E-rev) were used as primers. Reverse transcriptase extended fragments using primer C-rev (Fig. 4 A) Finally, reverse-extended fragments using primer E-rev (Fig.  4C ) located a major initiation site at position Ϫ3387 (24 nt downstream of the P5 TATA box). The existence of this transcript was confirmed by RT-PCR, cloning, and sequencing of a 90-bp fragment generated by using the P5L and E-rev oligonucleotides as forward and reverse primers, respectively (data not shown). Again, the P5 transcripts were observed only in some tissues, such as spleen (lane 3), liver (lane 5), and brain (lane 6), but not in others, such as uterus (lane 2). Very small amounts of P5 transcripts were detected in thymus (lane 4).
Multiple mRNAs Derived from the bcl-X Gene-The structure of the bcl-X 5Ј-flanking region is shown schematically in Fig. 5 . If all five promoters were used and the transcripts spliced to the coding region, at least five mRNAs differing in the 5Ј-noncoding leader exons (exons A-E) would be expected. Until now, mRNAs containing exons D and E had not been detected by cloning. However, we have detected and sequenced four mRNAs, one derived from the promoter P1, two containing exon B, and one containing exon C. The 5Ј structures of these mRNAs are shown in Fig. 6 , along with the nucleotide sequence around the start site. As previously described (1), we detected mRNA A, derived from the P1 promoter in all tissues analyzed.
There are at least three different mRNAs containing exon B sequences of various lengths, which originate from the use of three alternative 5Ј-donor splice sites. All these three mRNAs share the same 3Ј-acceptor splice at position Ϫ112 in exon A. Using cDNA cloning with RT-PCR, we detected only two of these mRNAs, one of which uses nt Ϫ553 as the 5Ј splice site (mRNA B1) and the other of which splices at nt Ϫ397 (mRNA B2). mRNA B1 was obtained from total RNA of mouse uterus and spleen by RT-PCR with the oligonucleotides P2L and ATGrev (Fig. 5 ) as forward and reverse primers, respectively. mRNA B2 was also previously described (1). Fang et al. (12) report evidence of the existence in B and T lymphocytes of a third mRNA containing exon B sequences with a 5Ј-splice site located at nt Ϫ197 (mRNA B3) (GenBank TM accession number MMU10102). We did not detect this mRNA in any of the tissues tested.
mRNA transcripts containing exon C were detected by nested RT-PCR of total RNA from mouse spleen using primers P3L and ATG-rev for the first PCR and P3S and AI-rev in the second round (Fig. 6, mRNA C) . The nucleotide sequence of all the transcripts we have detected did not show any open reading frames located upstream of the known coding region (Fig. 6) (4) .
We could not detect any mRNA transcripts containing exon D or exon E when we performed RT-PCR with primers P4L/P5L and ATG-rev followed by nested PCR with primers P4S/P5S and AI-rev from total RNA of tissues in which P4 and P5 were active as judged by primer extension assays (uterus and spleen for P4 and spleen, liver and brain for P5). These results suggest that either the proportion of these mRNAs is very low in the total RNA or that the PCR products were too long to be efficiently amplified in our assays. Moreover, RT-PCR products were generated with the primers P5L/E-rev and P4L/D-rev, and their sequences corresponded to exons E and D, respectively (data not shown).
Use of Different bcl-X Promoters Generates Specific Spliced Products and
Bcl-X mRNA Isoforms-The results described above showed tissue-dependent activities of the multiple promoter regions present in the bcl-X gene (Figs. 2 and 4) . P1, P2, and P4 are active in uterus and heart; only P1 and P2 are active in thymus; P1, P2, P3, and P5 are active in liver; and all promoters are active in spleen. The question arises as to the physiological relevance of alternative and tissue-specific promoter usage. Our results suggest that the selection of promoter usage would be involved in the regulation of the levels of the various bcl-X mRNAs. The differences in the 5Ј-noncoding exons of the transcripts may stabilize different secondary structures, which could play a role in generating specific spliced products. To test this possibility, we performed RT-PCR using forward primer oligonucleotides corresponding to each of the noncoding regions (primers P1, P2L, and P3L for exons A, B, and C, respectively) and a common reverse primer that hybridized specifically with the second translated exon (primer S/Lrev) (Fig. 7) . We choose RNA from four tissues in which the different transcripts are expressed (spleen, liver, brain, and thymus). Activation of P1 generated mainly bcl-X L and very little, if any, bcl-X S (Fig. 7A, lanes 2, 3, 4, and 8) . Transcripts containing exon B generated both bcl-X L and bcl-X S mRNAs, but with a higher proportion of the former in all tissues tested (Fig. 7B, lanes 2, 3, 4, and 6 ). Transcripts containing exon C were only detected in thymus and corresponded to both isoforms but with a higher proportion of bcl-X S relative to bcl-X L (Fig. 7C, lane 8) . This was unexpected, as P3 is active in spleen, liver, and brain (Fig. 4A) . Thus, a bcl-X isoform different from bcl-X L/S is likely generated from these transcripts. RT-PCR using oligonucleotide P3L as forward primer and a reverse primer whose sequence hybridized specifically with bcl-X ␥ (primer ␥-rev) revealed the presence of bcl-X ␥ mRNAs containing exon C in all the tissues analyzed (Fig. 8B) . In addition, bcl-X ␥ was found as a spliced product of transcripts containing exon B (Fig.  8A ) in all tissues tested, whereas no amplified product of this isoform was detected with transcripts derived from the P1 promoter (data not shown). Taken together the results suggest that independently of the cell type, the use of a specific promoter generates spliced transcripts specific for different Bcl-X isoforms.
DISCUSSION
The Bcl-2 family is known to control apoptosis induced by a wide range of agents. Some members of the family like Bcl-2 and Bcl-X L prevent apoptosis, whereas others, like Bax and Bcl-X S , induce cell death by dimerizing with Bcl-2 or Bcl-X L or by forming Bax-Bax dimers (4). In this way, the ratio between proapoptotic and antiapoptotic dimers acts as a "rheostat" which determines whether a given cell is going to die or to survive. Members of the Bcl-2 family with similar functions are not found in the same cell at the same time (15) . Thus, a pair of proteins with opposite effect, either Bcl-2/Bax or Bcl-X L /Bcl-X S depending on the cell type or developmental stage, forms the rheostat. To ensure a correct control of apoptosis, the levels of proteins present in a given specific rheostat must be precisely regulated. Bcl-X S and Bcl-X L are not the unique splice products from the bcl-X gene. In mice and rat, five different isoforms have been described, with opposite effects on programmed cell death (4, (12) (13) (14) . The control of apoptosis requires expression of the correct amount of each isoform, suggesting not only an accurate regulation of transcription but also of splicing of the bcl-X gene.
The experiments summarized in this paper demonstrate that the mouse bcl-X gene exhibits a complex structure, in particular around its 5Ј-UTR, which contains at least four different exons located upstream the unique open reading frame. Grillot et al. (1) report that the mouse bcl-X gene is transcribed from two TATA-less promoters located between Ϫ149 and Ϫ142 (P1) and between Ϫ655 and Ϫ727 (P2) (1). Our present study demonstrates that there are at least three additional promoters farther upstream: P3 located at Ϫ1886, P4 at Ϫ2721, and P5 at Ϫ3412 upstream of the translation initiation codon. These three novel promoters contain a TATA consensus sequence according to the weight matrix descriptions of eukaryotic RNA polymerase II promoter elements (21) . Very recently, the existence of transcripts originating from a promoter corresponding to our P3 has been reported for the human bcl-X gene and seems to be conserved in the mouse (22) .
Using immunohistochemical analysis, Krajewski et al. (15) report a strong Bcl-X expression in neurons from brain, in epithelial and cortical cells of the thymus, in red pulp granulocytes from spleen, in hepatocytes, in the loop of Henle of the kidney, and in endometrial cells (15) . We did not analyze all of these cell types, but we found bcl-X expression in all the tissues tested. In addition we have observed that the use of the different promoters varied markedly in the tissues analyzed. We found that P1 and P2 were active in all tissues tested, whereas P3, P4, and P5 showed a tissue-dependent pattern of activity. According to RNase protection and primer extension assays, P3 was active in spleen, liver, and kidney, P4 in uterus and spleen, and P5 in spleen, thymus, liver, and brain.
Analysis of the nucleotide sequence of the 5Ј-flanking region of the mouse bcl-X gene led to the identification of several consensus motifs for the binding of transcription factors. The physiological significance of these motifs remains to be determined. It has been described that expression of the different isoforms of bcl-X gene is controlled by several stimuli acting via various transcription factors, including Ets-1 and 2, GATA-1, NF-B, AP-1, and STAT (signal transducers and activators of transcription) factors (23) . For instance, the Ets-2 transcription factor inhibits apoptosis induced by colony-stimulating factor 1 deprivation of macrophages through a Bcl-X L -dependent mechanism (23) . In particular, several reports show that the bcl-X L isoform is induced upon the activation of the Jak-Stat-signaling pathway (24 -29) . On the other hand, the involvement of 5Ј-flanking NF-B-like sites in regulation of bcl-X gene expression has been recently reported (30) .
We have previously shown that steroid hormones dexamethasone and progesterone induce bcl-X expression and increase the bcl-X L /bcl-X S ratio in endometrial cells (20) . Studies from other authors confirm that steroid hormones control bcl-X transcription in different tissues (31) (32) (33) . Transient transfection experiments with a reporter gene under the control of the mouse bcl-X P1, P2, or P3 promoters have demonstrated a hormone-dependent expression, 2 although no consensus hormone regulatory element motifs are found in the neighborhood of these promoters. This suggest that steroid receptors might control bcl-X expression by interacting with other transcription factors, such as AP1, NF-B, and STAT5, rather than by a specific interaction with hormone regulatory element, as has been recently shown in other systems (34 -36) .
The activation of the five promoters described in this study would generate at least five mRNAs with different 5Ј-UTRs. Multiple promoter usage is a mechanism that offers the possibility of responding to distinct combinations of factors present in the different tissues. Using RT-PCR, we have found only some of these transcripts. The mRNA A, which is generated by activation of P1, starts at nt Ϫ144 in exon A and is expressed in all analyzed tissues. We also identified two different types of mRNAs containing exon B sequences that differ in the selection of the 5Ј-donor splice site. We cloned mRNA B1 from the spleen, whereas mRNA B2 had been described in several reports and corresponds to transcripts generating three isoforms, long, short, and ␥ (GenBank TM accession numbers U51278, U51279, and U51277, respectively), as confirmed here by RT-PCR. A third type of transcripts containing exon B sequences (mRNA B3) can been found in GenBank TM (accession number MMU10102). Its sequence corresponds to bcl-X ⌬TM , a bcl-X isoform lacking the transmembrane domain (Fig. 1A) (12) . In our study we did not detect this mRNA, but we found an mRNA containing exon C sequences (mRNA C). mRNA C generated only bcl-X ␥ in spleen, brain, and liver, whereas in thymus it generated the two ubiquitous isoforms, bcl-X S and bcl-X L . According to the primer extension assays, P3 is not active in thymus, suggesting that the detected amplification products are derived from promoter regions located farther upstream.
Given the important role of bcl-X in controlling programmed cell death, its expression should be precisely regulated. We suggest that multiple promoter usage in the mouse bcl-X gene provides for tissue specificity and variations in expression levels of the different spliced products. The existence of multiple transcripts differing in their 5Ј-UTR and likely in their secondary structure could determine the generation of specific spliced products. In this way, external signals, by influencing promoter selection in a specific tissue, would determine the formation of specific Bcl-X isoforms. It has been described that promoter sequences influence the selection of the splice site through an interaction between the transcription machinery and serinearginine proteins (SR) involved in the splicing process (17) . Although far from being complete, our results describe for the first time the complexity of the structure of the 5Ј-flanking region of the bcl-X gene and provide the basis for future studies on the physiological relevance of multiple promoter usage and alternative splicing in controlling programmed cell death.
FIG. 7.
RT-PCR from total RNA obtained from spleen, brain, liver, and thymus. Exon-specific oligonucleotides were used as forward primers (P1, P2L, and P3L for A, B, and C, respectively), and S/L-rev (which hybridizes specifically with the stop codon of bcl-X (L/S)) was used as the reverse primer in thymus. For the other tissues it was necessary to perform semi-nested PCRs using S/L(II)-rev (corresponding to the 5Ј-end of the second translated exon) as the reverse downstream primer. A, amplified products generated by P1. B, products generated by transcripts containing exon B. C, products generated by transcripts containing exon C. PCR-products were resolved in a 1.5% agarose gel and transferred to a nylon plus membrane. A Southern blot was performed by using as probe a fragment containing sequences from exon A. The lengths of the L and S products are indicated. The schemes on the top indicate the positions of the primers and the corresponding transcripts. M, molecular mass standards. ORF, open reading frame.
FIG. 8.
RT-PCR from total RNA obtained from spleen, brain, liver, and thymus. Semi-nested PCR was performed with the exon-specific oligonucleotides: P2L and P3L as forward primers (for A and B, respectively) and ␥-rev followed by AII-rev as reverse primers. A, products containing exon B. B, products generated by transcripts containing exon C. PCR products were resolved in a 1.5% agarose gel and transferred to a nylon plus membrane. A Southern blot was performed by using a fragment containing sequences from exon A as probe. The schemes on the top indicate the positions of the primers and the length of the transcripts. M, molecular mass standards.
